AVANIR Pharmaceuticals's revenue per share for the
three
months ended in Sep. 2014 was €0.15.
AVANIR Pharmaceuticals's revenue per share for the trailing twelve months (TTM) ended in Sep. 2014 was €0.53.
Warning Sign:
AVANIR Pharmaceuticals revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of AVANIR Pharmaceuticals was 31.50% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 99.10% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 124.80% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 0.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for AVANIR Pharmaceuticals's Revenue per Share or its related term are showing as below:
FRA:AV2B'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0 Med: -9.1 Max: 160.4
Current: 99.1
During the past 13 years, AVANIR Pharmaceuticals's highest 3-Year average Revenue Per Share Growth Rate was 160.40% per year. The lowest was 0.00% per year. And the median was -9.10% per year.
FRA:AV2B's 3-Year Revenue Growth Rate is not ranked
in the Drug Manufacturers industry.
Industry Median: 6.4
vs FRA:AV2B: 99.10
AVANIR Pharmaceuticals Revenue per Share Historical Data
The historical data trend for AVANIR Pharmaceuticals's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AVANIR Pharmaceuticals's Revenue per Share
For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVANIR Pharmaceuticals's PS Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where AVANIR Pharmaceuticals's PS Ratio falls into.
AVANIR Pharmaceuticals Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
AVANIR Pharmaceuticals's Revenue Per Share for the fiscal year that ended in Sep. 2014 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.53
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVANIR Pharmaceuticals (FRA:AV2B) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
AVANIR Pharmaceuticals Revenue per Share Related Terms
Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
AVANIR Pharmaceuticals (FRA:AV2B) Business Description
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:AV2B has been successfully added to your 